IRE1通路与肿瘤

内质网应激是细胞内广泛存在的一种应激反应。研究表明，内质网应激与肿瘤的发生发展密切相关。针对内质网应激及其相应信号通路进行肿瘤的预防或治疗受到了广泛关注。IRE1(inositol-requiring enzyme 1)通路是内质网应激诱发的最保守的信号通路。研究证实，IRE1及其主要的下游效应分子剪切型X 盒结合蛋白1与肿瘤进展密切相关。本文对IRE1通路与肿瘤发生发展、血管新生、肿瘤转移、肿瘤耐药性和恶性程度的相关性进行了阐述，同时分析了IRE1在不同肿瘤样本中的突变率、突变类型与病人存活状态的关系。作为肿瘤治疗的有效靶点，针对IRE1通路的调控能够有效延缓肿瘤的发生发展。

Inositol-requiring Enzyme 1 Pathway and Tumor

Endoplasmic reticulum (ER) stress is a widespread stress response in cells and increasing evidence strongly demonstrated that ER stress is closely related to tumorigenesis and tumor progression. Thus, growing attentions have been focusing on ER stress for cancer therapy. The inositol-requiring enzyme 1 (IRE1) signaling pathway is one of the most conserved pathways induced by ER stress across distinct species. As reported, IRE1 and its main downstream effector, spliced X-box binding protein 1 (XBP1), is tightly correlated to tumorigenesis, tumor growth, angiogenesis, metastasis, chemoresistance and tumor malignance. Here, we summarize the roles of IRE-1 in tumor progression, as well as the underlying molecular mechanisms. In addition, we found that there are strong connections between cancer patient survival states and IRE1 mutation with data extracted from public cancer databases. All these results strongly indicate that inhibiting the activation of the IRE1/XBP1 pathway could slow down tumorigenesis and tumor development, which suggests that IRE1 is an important drug target for cancer treatment and cancer therapy.